Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20467512 | 0.84 | HPGD (0.67) | HPGDNPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL20467511 | 0.79 | HPGD (0.77) | HPGDNPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL20467485 | 0.79 | HPGD (0.97) | HPGDNPC1RAB9ANAMPTALDH1A1 | |
| SCHEMBL17600738 | 0.78 | SPHK2 (0.59) | HPGDNPC1RAB9ANAMPTMEN1 | |
| SCHEMBL17600741 | 0.78 | SPHK2 (0.59) | HPGDNPC1RAB9ANAMPTMEN1 | |
| SCHEMBL26322484 | 0.78 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2APDK2 | |
| SCHEMBL15583893 | 0.78 | HPGD (1.00) | HPGDNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL20467460 | 0.78 | HPGD (1.00) | HPGDNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL8341295 | 0.77 | SPHK2 (0.62) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1457983 | 0.77 | HPGD (0.55) | HPGDNPC1RAB9ANAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230052363-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-16 | — | — | US | disclosed |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-03-26 | — | — | US | disclosed |
| WO-2018145080-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310390-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | GCDH, HPGD, HAGH | HPGD 2/4885NPC1 1045/4885RAB9A 2967/4885 |
| US-20200095206-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | HPGD 1/4885NPC1 2242/4885RAB9A 3884/4885 |
| US-20230052363-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | GLS, REN, PTGS1 | HPGD 4/4885NPC1 2517/4885RAB9A 1973/4885 |
| US-11718589-B2 | Compositions and methods of modulating short-chain dehydrogenase | HPGD, GCDH, HPGDS | HPGD 1/4885NPC1 2242/4885RAB9A 3884/4885 |
| US-20230322684-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE | HPGD, GCDH, HPGDS | HPGD 1/4885NPC1 2242/4885RAB9A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.